A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants
Starting soon · Phase 1 · Has a placebo group
Conditions studied: Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
In brief
The main objective of this trial is to evaluate the safety and reactogenicity of mRNA-1469
Key facts
- Study ID
- NCT07737717
- Run by
- ModernaTX, Inc.
- People needed
- 84
- Starts
- 2026-07-31
- Expected to finish
- 2027-09-30
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Canadian Center for Vaccinology — Halifax, Nova Scotia, Canada
- Colchester Research Group — Truro, Nova Scotia, Canada
- Centricity Research Toronto LMC Multispecialty — Toronto, Ontario, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.